ERBB2 and breast cancer: A dose-escalation and expansion phase 1 study (NCT02564900) evaluated the safety and activity of T-DXd in patients with advanced HER2 low-expressing solid tumors including 47 hormone receptor-positive breast cancer patients and 7 TNBC patients[83].